Lipopolysaccharide pretreatment modulates the disease course in experimental autoimmune encephalomyelitis

Abigail C. Buenafe, Dennis N. Bourdette

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Treatment with the bacterial product lipopolysaccharide (LPS) prior to the induction of experimental autoimmune encephalomyelitis (EAE) consistently led to a delayed onset of disease but not to a reduction in disease severity. T cell proliferation was reduced in LPS-treated mice, due at least in part to a loss in antigen presenting cell function. T cell and macrophage infiltration into the CNS was delayed and TNFα production was diminished in LPS pre-treated mice, consistent with the delay in disease onset. Real-time PCR analysis of gene expression in the CNS of LPS or saline pre-treated mice demonstrated an early induction of TNFα, TGFβ, IFNβ, and SOCS3 in the LPS pre-treated mice. Thus, exposure to LPS prior to EAE induction affects antigen presentation and may modulate the expression of inflammatory regulators that impact the autoimmune disease course.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalJournal of Neuroimmunology
Volume182
Issue number1-2
DOIs
StatePublished - Jan 1 2007

Keywords

  • Anti-inflammatory mediators
  • Antigen presentation
  • EAE
  • LPS
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Lipopolysaccharide pretreatment modulates the disease course in experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

  • Cite this